FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892058094> ?p ?o ?g. }

• W2892058094 endingPage "5" @default.
• W2892058094 startingPage "1" @default.
• W2892058094 abstract "Mepolizumab is a humanized monoclonal antibody which targets interleukin-5 (IL-5) and is nowadays available in many countries for add-on biological therapy of severe eosinophilic asthma. Although the approval of mepolizumab use in clinical practice has been made possible by several successful pre-marketing controlled trials, so far only a very few studies have been performed in a real-life setting. Within such a context, our present observational investigation refers to 14 patients with refractory eosinophilic asthma, currently treated with mepolizumab at the Respiratory Unit of “Magna Græcia” University Hospital located in Catanzaro, Italy, whose anti-IL-5 treatment began between June 2017 and January 2018. These patients experienced a significant increase in asthma control test (ACT) score, that was evaluated at baseline (13.64 ± 3.00), as well as after 4 weeks (18.86 ± 3.15; p < 0.0001) and 24 weeks (20.07 ± 1.94; p < 0.0001) of add-on therapy with mepolizumab. This relevant improvement in symptom control was paralleled by a dramatic fall of blood eosinophil numbers, counted at baseline (647.1 ± 274.7 cells/μl), and at the 4th (147.8 ± 66.5 cells/μl; p < 0.0001) and 24th week (98.6 ± 40.3 cells/μl; p < 0.0001) after starting add-on treatment with mepolizumab. These changes were associated with significant and stable increases in FEV1, which was recorded at baseline (1389 ± 454.3 mL), as well as after 4 weeks (1711 ± 482.3 mL; p < 0.001) and 24 weeks (1701 ± 456.0 mL; p < 0.01). Moreover, in comparison to the 6 months preceding the beginning of treatment with mepolizumab, after 24 weeks of anti-IL-5 therapy significant decreases were detected with regard to exacerbation numbers (from 3.64 ± 1.86 to 1.0 ± 0.78; p < 0.001) and oral intake of prednisone (from 24.11 ± 10.36 mg/day to 1.78 ± 3.82 mg/day). Therefore, these preliminary data referring to our single-centre observational study corroborate, in a real-life environment, the efficacy of mepolizumab for treatment of patients with exacerbation-prone, corticosteroid-refractory, severe eosinophilic asthma." @default.
• W2892058094 created "2018-09-27" @default.
• W2892058094 creator A5018421075 @default.
• W2892058094 creator A5028306950 @default.
• W2892058094 creator A5037532238 @default.
• W2892058094 creator A5038462358 @default.
• W2892058094 creator A5061103978 @default.
• W2892058094 date "2018-12-01" @default.
• W2892058094 modified "2023-10-11" @default.
• W2892058094 title "Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study" @default.
• W2892058094 cites W1965484089 @default.
• W2892058094 cites W1970648068 @default.
• W2892058094 cites W1994585625 @default.
• W2892058094 cites W2005749129 @default.
• W2892058094 cites W2009016013 @default.
• W2892058094 cites W2021701428 @default.
• W2892058094 cites W2032382363 @default.
• W2892058094 cites W2042788227 @default.
• W2892058094 cites W2062918919 @default.
• W2892058094 cites W2075699130 @default.
• W2892058094 cites W2077763487 @default.
• W2892058094 cites W2095754126 @default.
• W2892058094 cites W2112649669 @default.
• W2892058094 cites W2121739711 @default.
• W2892058094 cites W2138355864 @default.
• W2892058094 cites W2208860124 @default.
• W2892058094 cites W2312870247 @default.
• W2892058094 cites W2341639201 @default.
• W2892058094 cites W2467880758 @default.
• W2892058094 cites W2515998798 @default.
• W2892058094 cites W2602230319 @default.
• W2892058094 cites W2604291894 @default.
• W2892058094 cites W2620841583 @default.
• W2892058094 cites W2733899860 @default.
• W2892058094 cites W2754586014 @default.
• W2892058094 cites W2755340325 @default.
• W2892058094 cites W2765417286 @default.
• W2892058094 cites W2773169119 @default.
• W2892058094 cites W2774019602 @default.
• W2892058094 cites W2777899893 @default.
• W2892058094 cites W2790881175 @default.
• W2892058094 cites W2791261363 @default.
• W2892058094 cites W2808616632 @default.
• W2892058094 cites W2810825824 @default.
• W2892058094 cites W2884019861 @default.
• W2892058094 cites W4210991698 @default.
• W2892058094 cites W4211175431 @default.
• W2892058094 doi "https://doi.org/10.1016/j.pupt.2018.09.006" @default.
• W2892058094 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30217438" @default.
• W2892058094 hasPublicationYear "2018" @default.
• W2892058094 type Work @default.
• W2892058094 sameAs 2892058094 @default.
• W2892058094 citedByCount "55" @default.
• W2892058094 countsByYear W28920580942018 @default.
• W2892058094 countsByYear W28920580942019 @default.
• W2892058094 countsByYear W28920580942020 @default.
• W2892058094 countsByYear W28920580942021 @default.
• W2892058094 countsByYear W28920580942022 @default.
• W2892058094 countsByYear W28920580942023 @default.
• W2892058094 crossrefType "journal-article" @default.
• W2892058094 hasAuthorship W2892058094A5018421075 @default.
• W2892058094 hasAuthorship W2892058094A5028306950 @default.
• W2892058094 hasAuthorship W2892058094A5037532238 @default.
• W2892058094 hasAuthorship W2892058094A5038462358 @default.
• W2892058094 hasAuthorship W2892058094A5061103978 @default.
• W2892058094 hasConcept C126322002 @default.
• W2892058094 hasConcept C142724271 @default.
• W2892058094 hasConcept C151730666 @default.
• W2892058094 hasConcept C181901479 @default.
• W2892058094 hasConcept C23131810 @default.
• W2892058094 hasConcept C2776042228 @default.
• W2892058094 hasConcept C2777037409 @default.
• W2892058094 hasConcept C2777832160 @default.
• W2892058094 hasConcept C2778690821 @default.
• W2892058094 hasConcept C2779343474 @default.
• W2892058094 hasConcept C2779758542 @default.
• W2892058094 hasConcept C71924100 @default.
• W2892058094 hasConcept C74172505 @default.
• W2892058094 hasConcept C86803240 @default.
• W2892058094 hasConcept C90924648 @default.
• W2892058094 hasConceptScore W2892058094C126322002 @default.
• W2892058094 hasConceptScore W2892058094C142724271 @default.
• W2892058094 hasConceptScore W2892058094C151730666 @default.
• W2892058094 hasConceptScore W2892058094C181901479 @default.
• W2892058094 hasConceptScore W2892058094C23131810 @default.
• W2892058094 hasConceptScore W2892058094C2776042228 @default.
• W2892058094 hasConceptScore W2892058094C2777037409 @default.
• W2892058094 hasConceptScore W2892058094C2777832160 @default.
• W2892058094 hasConceptScore W2892058094C2778690821 @default.
• W2892058094 hasConceptScore W2892058094C2779343474 @default.
• W2892058094 hasConceptScore W2892058094C2779758542 @default.
• W2892058094 hasConceptScore W2892058094C71924100 @default.
• W2892058094 hasConceptScore W2892058094C74172505 @default.
• W2892058094 hasConceptScore W2892058094C86803240 @default.
• W2892058094 hasConceptScore W2892058094C90924648 @default.
• W2892058094 hasLocation W28920580941 @default.
• W2892058094 hasLocation W28920580942 @default.
• W2892058094 hasOpenAccess W2892058094 @default.

• next